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Abstract: 
Objectives: Significant liver disease may develop in HIV mono-infected patients, usually associated with fatty liver and/or cART exposure. 
We estimated the prevalence and predictors of hepatic steatosis and fibrosis as assessed by ultrasound and transient elastography (TE).  
Methods: We enrolled 125 consecutive HIV mono-infected patients who underwent ultrasound and TE. Clinical, biochemical, 
immunological, virological features and medication history were analysed.  
Results: Mean age was 39.5±10.3 years and 91% were male. Metabolic syndrome (MS) was present in 9.8%, diabetes in 5.6%, 
hypertension in 9.7%, dyslipidemia in 32.8%. Increased AST and ALT were found in 5.6% and 16.8% respectively. Eighty-five (68%) 
patients were on cART (median length of treatment of 3 years, IQR 0-17). Hepatic steatosis was detected in 61 (55%) patients and was 
independently associated with male sex (OR 14.6, 95%CI 1.44-148.17), age (OR 1.082, 95%CI 1.01-1.16), HOMA (OR 2.56, 95%CI 1.101-
5.96) and GGT (OR 1.037, 95%CI 1.007-1.075). Significant fibrosis (stiffness >7.4 KPa) was present in 22 patients (17.6%) and was 
significantly associated with MS (OR 3.99, 95%CI 0.992-16.09).  
Conclusions: Liver fibrosis can develop in asymptomatic HIV mono-infected patients. This is likely associated with NAFLD and usually 
manifests with normal transaminases. Non-invasive screening for the presence of NAFLD and fibrosis should be considered in the routine 
care of such patients.  
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Introduction 
Liver disease is an increasingly important issue in patients with HIV infection and is a leading cause of mortality second only to AIDS (1). 
This increase in liver-related morbidity and mortality is a consequence of the dramatic decrease in early AIDS-related deaths due to the 
introduction of effective highly active antiretroviral therapy (HAART) (2). Apart from viral co-infections with HCV and/or HBV, non-
alcoholic fatty liver disease (NAFLD) in the setting of metabolic syndrome or antiretroviral therapy exposure is an emerging cause. 
NAFLD is the hepatic manifestation of the metabolic syndrome (MS) and consists of a broad spectrum of diseases ranging from simple 
steatosis to non-alcoholic steatohepatitis (NASH) that could potentially lead to cirrhosis and hepatocellular cancer (3). It has a prevalence 
of 20% in the general population of industrialized countries but can rise up to 50 % in HIV-infected people, due to the additive effects of 
antiretroviral treatment, lipodystrophy and the HIV virus per se (4, 5). Indeed, NAFLD could represent a long-term toxicity of HAART as 
both nucleoside reverse-transcriptase inhibitor (NRTIs) and protease inhibitors (PIs) are associated with the onset of insulin resistance 
and/or mitochondrial toxicity (6).  
Non-invasive fibrosis tests (NITs) are increasingly used for the assessment of fibrosis in patients with NAFLD (7). Of these, transient 
elastography (TE) has advantages over serum markers in patients with HIV, as it is not influenced by concomitant antiretroviral 
medication, HIV replication, CD4 cell count, or non-liver inflammatory processes (8, 9).  
In this study, we evaluated the prevalence and predictors of hepatic steatosis and fibrosis as assessed by ultrasound and simple NITs 
and TE respectively in a consecutive unselected cohort of HIV mono-infected patients.  
 
 
 
Methods 
Study population 
Over a 6-month period, we included 125 consecutive patients with HIV mono-infection who were followed up at the dedicated HIV 
outpatient clinic at Hippokration General Hospital in Athens. Patients with HCV or HBV co-infection were excluded. The study was 
approved by the hospital ethical committee.  
All patients had baseline laboratory investigations, and epidemiological and anthropometric features were recorded. BMI was calculated 
as weight (Kg)/height (m2).  Waist circumference was measured at the midpoint between the lower border of the rib cage and the iliac 
crest. The presence of lipoatrophy and/or lipohypertrophy was assessed during clinical examination. 
An increase in transaminases level was defined as values of AST and ALT more than 39 U/L and 41 U/L, respectively. MS was diagnosed 
according to the American Heart Association/National Heart, Lung and Blood Institute criteria (10). Insulin resistance (IR) was assessed by 
HOMA index (fasting glucose mg/dl x fasting insulin mg/dl/22.5), and values more than 3 were considered diagnostic. All patients had a full 
liver screen performed, including viral hepatitis serology, autoimmune serology, ferritin and transferrin saturation, a1-antithrypsin levels 
and ceruloplasmin levels. Commercially available enzyme immunoassays were used for the detection of HBV markers (HBsAg, HBeAg, anti-
HBe, anti-HBc), anti-HCV and anti-HDV and commercially available polymerase chain reaction assays for the detection of serum HBV DNA 
and HCV RNA. In patients who were anti-HBc and anti-HBsAg positive, HBV DNA was determined. 
Patients were interviewed about their smoking habits (packs/year) and drinking pattern; an alcohol consumption of more than 20g/day 
for women and 30g/day for men was considered as alcohol abuse.  
A detailed HIV infection history was available, including duration of infection, CD4+ count(n°/µL) and HIV viral load (RNA copies/µL), 
current and previous antiretroviral therapy and duration of treatment. 
Liver stiffness and steatosis assessment  
All patients underwent ultrasound and TE by dedicated operators (DC and ET respectively) after at least six hours of fasting. The presence 
and severity of hepatic steatosis was evaluated by ultrasound; in particular, the grade of HS was diagnosed according to characteristic 
imaging features, namely bright liver pattern, liver-kidney contrast, vascular blurring and/or deep hepatic attenuation. 
TE was performed with FibroScan®(Echosens; Paris, France) and the results were expressed in Kilopascals (KPa). The final value was 
calculated as the mean of ten valid measurements, obtained by placing the probe on the patient’s skin between the ribs at the level of 
the right lobe of the liver in dorsal decubitus position. In order to ensure a reliable determination of liver stiffness, an interquartile range 
for measurements within 30% and ratio of success rate of measurements (number of total measurements/number of valid acquisition) 
>60% were considered adequate. Liver stiffness values >7.4 kPa were considered suggestive of significant fibrosis.  
The presence of significant fibrosis (≥F2) was evaluated with the APRI index, which consists of AST and platelet count, with validated 
cut-off values of <0.5 and >1.5 for ruling out or diagnosing the target condition respectively (11). The presence of advanced fibrosis (≥F3) 
was evaluated by the FIB4 score, which consists of age, AST, ALT and platelet count and validated cut-offs values of <1.45 and >3.25 for 
ruling out or in advanced fibrosis respectively were used (12).  
Statistical analysis 
All data were analysed using the statistical package SPSS (version 22.0, IBM, New York, NY, USA). Statistical analysis was performed using 
t-test, ANOVA, Mann-Whitney test or Kruskal-Wallis test for comparisons of continuous variables between or among groups, corrected 
chi-squared method or two-tailed Fisher’s exact test for comparisons of qualitative data and Spearman’s co-efficient for correlations of 
quantitative data, when appropriate. Multivariate analysis was performed using logistic regression models. Only variables with a P value 
0.10 at univariate analysis were entered in the multivariate analysis models. A two-tailed P value <0.05 was considered to be statistically 
significant. 
 
 Results 
Baseline characteristics 
In total, 125 HIV mono-infected patients were enrolled in the study. The mean age was 39.5 years and 91% were males. Baseline 
characteristics are shown in Table 1. The corresponding mean values of BMI and waist circumference were 24.6±2.8 kg/m2 and 91.8±14.3 
cm, while MS was present in 12 patients (9.8%). In particular, 12 patients (9.7%) had hypertension, 7 (5.6%) had diabetes and 6 (7.1%) 
were insulin resistant, with a median HOMA index of 1.44 (IQR 0.26-7.07). Dyslipidaemia was present in 41 patients (32.8%), abnormal 
LDL in 65 patients (52%) and hypertriglyceridemia in 49 patients (39%). Patients on fibrates (n=2) were considered to have 
hypertriglyceridaemia) and patients on statins (n=5) were considered to have high LDL irrespective of lipid levels. 
Five patients reported drinking above the recommended limits, however as their intake was only moderately increased (<60 units per 
week) we included them in the analysis. 
Abnormal transaminases were prevalent only in a minority of patients, with increased AST and ALT values in 7 and 21 cases respectively 
(5.6% and 16.8%).  
Eighty-five (68%) patients have been on anti-HIV treatment for a median duration of 3 (IQR 0-17) years. The most common drugs used 
were PIs in 45.1% of treated patients, while thymidine analogues, NNRTIs and nevirapine accounted for the 29.5%, 27% and 4.8% of 
treatment, respectively. The median duration of HIV viral infection was 6 (IQR 0-26) years, while thirty-five (36.8%) patients had 
lipodystrophy. No patients presented with AIDS and median CD4 count was 480 copies/mmc  (9-1740) , while mean HIV viral load was 
333732 ± 144520 copies/mL.  
Prevalence and predictors of hepatic steatosis 
Fatty liver was detected by ultrasound in 61 patients (55%), of who 3.6% had severe steatosis. As shown in table 2, in univariate analysis, 
steatosis was associated with male sex, presence of metabolic syndrome and increasing age, waist circumference and BMI. MS had a 
prevalence of 18% and 2% in patients with and without steatosis (p=0.006), while BMI values were 25.59 ± 2.99 and 23.37 ± 2.19 kg/m2, 
respectively (p=0.001). HOMA values were significantly increased in the subset of patients with steatosis (2.01 ± 1.37 vs. 1.26 ± 0.65, 
p=0.002), however the presence of IR, defined by HOMA values more than 3, was not significantly different between the two groups. 
No association with lipid profile was found, apart from the presence of hypertrygliceridaemia. Of all liver enzymes, only GGT was higher 
in patients with steatosis. Neither the duration nor the severity of HIV was associated with steatosis, as well as the use of antiviral agents. 
Prevalence of steatosis on ultrasound was lower in treatment-naïve patients however this did not reach statistical significance. In the 
multivariate analysis, steatosis was independently associated with male sex (OR 14.6; 95% CI 1.44-147.9; p=0.02), increasing age (OR 
1.083; CI 95% 1.012-1.158; p=0.02), increasing HOMA index (OR 2.56; CI 95% 1.102-5.93; p=0.03) and GGT (OR 1.038; CI 95% 1.002-
1.075; p= 0.039). Interestingly, the association with either MS or the use of past or current antiviral treatment, was no longer 
significant. Results did not significantly change when categorical variables were analysed as continuous (data not shown).  
Prevalence and predictors of liver fibrosis 
Considering as threshold a stiffness value of 7.4 KPa, significant fibrosis (≥F2) was present in 22 patients (17.6%), whereas 54 patients 
(43%) had stiffness values >5.5 KPa. On the other hand, values >10 Kpa, suggestive of advanced fibrosis (≥F3), were detected in only 5 
patients (4%). Interestingly, only a minority of patients with significant fibrosis as assessed by TE had abnormal transaminases, with 
deranged AST and ALT in 2 (9.1%) and 4 (18.1%) patients respectively. 
In the univariate analysis, no association between significant fibrosis and fatty liver, IR and the lipid profile was noted. Similarly, there 
was no significant association with the severity or duration of the HIV infection, the duration of treatment or different treatment 
regimens, as well as the treatment status. Conversely, increasing age and BMI were significantly associated with significant fibrosis. 
Moreover, MS was significantly associated with stiffness values >7.4 KPa (27.3% vs. 5.8 %, p=0.04). In the multivariate analysis, the only 
factor independently associated with fibrosis was presence of the MS (OR 3.99: 95% CI 0.992-16.09; p=0.05). Results did not significantly 
change when categorical variables were analysed as continuous (data not shown).  All the above is summarized in table 3. 
FIB4 score values of >3.25, suggestive of advanced fibrosis (≥F3), were seen in just 1 patient (0.8%), whereas more than 95% of patients 
(n=119) had normal values, namely <1.45. Similarly, APRI index > 1.5, suggestive of significant fibrosis (≥F2), was seen only in 2 patients 
(1.6%), while normal values <0.5 were found in 117 subjects (93.6%). 
Among patients with FIB4<1.45 (n=119), TE values >7.4 KPa and >10 KPa were present in 19 (16%) and 4 (3.4%) subjects, respectively. 
In patients with APRI values <0.5 (n=117), TE was suggestive of significant and advanced fibrosis in 20 (17%) and 4 (3.4%) patients 
respectively.  
Among patients with Fibroscan values >7.4 KPa, the majority had FIB4 <1.45 (19/22, 86.4 %) and APRI <0.5 (20/22 patients, 90.9 %). 
Conversely, FIB4 was <1.45 in 100 (97%) patients with TE values <7.4 KPa and in 115 (95.8%) of patients with TE values <10 KPa. All the 
above is summarized in Table 4. 
In the subgroup of 50 patients without ultrasonographic evidence of fatty liver, 7 had evidence of significant fibrosis (14%) based on 
elastography, while the FIB4 was suggestive of advanced fibrosis in only 1 subject, but no predictive factors could be found. 
 
Discussion 
In our study, we showed that NAFLD is prevalent in more than 50% of patients with HIV mono-infection and more importantly that 
significant liver fibrosis is prevalent in 17.6% of these otherwise asymptomatic patients. These results are of concern, particularly as they 
were observed in young and non-obese patients with no clear risk factors for NAFLD and fibrosis. Therefore, they emphasize the 
emerging significance of liver disease and in particular the importance of previously under-recognized NAFLD in patients with HIV 
infection.  
The current “gold standard” for the assessment of non-alcohol related liver injury is histology.  Nevertheless, liver biopsy is an invasive 
procedure that cannot be used for screening asymptomatic individuals, therefore we used transient elastography (TE) with Fibroscan®, 
which has demonstrated an acceptable diagnostic accuracy in the detection of advanced fibrosis and cirrhosis in NAFLD (13). 
Data on the prevalence and predictors of NAFLD in HIV mono-infected patients are limited, as most of existing studies have focused on 
patients with HIV/HCV co-infection. In our study, NAFLD as detected by ultrasound was prevalent in more than half of the included 
patients. However, one could safely assume that the true prevalence of NAFLD is even higher, as ultrasound can detect steatosis only 
when more than 20-30% of hepatocytes are affected. Interestingly, most patients with NAFLD had normal transaminases, confirming 
their lack of accuracy in diagnosing NAFLD or NASH (14). NAFLD was independently associated with male sex, increasing age and HOMA 
values. Surprisingly, neither MS nor obesity were significantly associated with the presence of steatosis. This probably reflects the 
evaluated cohort, as the majority of patients were non-obese and did not have metabolic syndrome. The association of NAFLD with 
insulin resistance confirms previous observations that the HIV status predisposes to steatosis, through the virus itself, the direct or 
metabolic effects of the anti-retroviral medication and lipodystrophy (15). All these factors may indeed contribute to an even more 
severe liver disease compared to uninfected subjects, as shown by Vodkin et al, who compared liver histology of 33 patients with HIV 
associated NAFLD and 33 patients with primary NAFLD and found higher rates of NASH and of features of liver disease, namely lobular 
inflammation and acidophil bodies (16). Finally, an element of undisclosed alcohol abuse could have also contributed to the higher than 
expected steatosis prevalence in our cohort. 
In our study, there was no association of either the duration and severity of HIV infection or of the past or present use of HAART with 
steatosis. In a study by Crum-Cianflone, steatosis was found on ultrasound in 31% and at histology in 33% of 216 HIV mono-infected 
patients and there was no association with HIV viral load, duration of infection, or antiretroviral therapy (17). A similar prevalence of 
NAFLD at ultrasound (31%) was found in an Asian cohort of 435 HIV mono-infected patients and was associated with high BMI, 
dyslipidemia, and high ALT/AST ratio, but not with HIV-related factors (18). Conversely, in a cohort of 225 HIV mono-infected patients, 
steatosis detected by CT scan was prevalent in 37% of patients and was associated with cumulative NRTI exposure (OR 1.12) (19).  
However, in the latter study the mean time exposure to NRTI was approximately 10 years, compared to 4.8 years reported in our study. 
Therefore, the lack of association between NRTIs treatment and hepatic steatosis in the current study might be related to the shorter 
exposure to these drugs.  
Moreover, data are also emerging on steatosis in HIV mono-infected patients assessed by controlled attenuation parameter (CAP) 
measurements with Fibroscan. In particular, Macias et al demonstrated the presence of steatosis by CAP in 201 (40%) of 505 HIV mono-
infected patients, with BMI being the main predictor of fatty liver. A similar prevalence of 49% was reported by Sulyok et al, who found 
a significant association between high CAP values and BMI, diabetes and hypertension. These results are in line with our data even if 
they are reported in a cohort of more obese patients (20, 21). 
For the non-invasive evaluation of fibrosis using TE, we considered stiffness values >7.4 kPa as suggestive of significant fibrosis, thus 
classifying 22 patients (17.6%) in this category. Although data about the use of TE in HIV mono-infected patients are limited and no 
validated cut-off values are available, in principle TE appears to be the best non-invasive tool in such patients. TE has excellent accuracy 
for the detection of liver cirrhosis and is moderately accurate for significant fibrosis (22, 23). However, it is safe to assume that patients 
with stiffness values >7.4 would have some degree of fibrosis, even if this did not reach F2.  In our analysis, the presence of significant 
fibrosis using TE was independently associated with MS but not with any parameters of the HIV infection. The impact of antiretroviral 
therapy on liver fibrosis is controversial as evidenced by conflicting reports on worsening with long term use of HAART, especially 
didanosine or stavudine (24, 25), absence of significant effect (26), or even improvement in the course of antiretroviral treatment with 
PIs (27, 28).  
Few other studies have evaluated the presence of fibrosis in unselected mono-infected patients with HIV and none correlated this with 
metabolic risk factors. In a cohort of 258 patients with HIV mono-infection, stiffness of >7.2 KPa was prevalent in 11.2%, however there 
were no data on the presence of steatosis and no correlation with metabolic parameters (29). In a similar cohort of 93 patients, stiffness 
of >5.3 KPa was prevalent in 42% with no information on NAFLD and/or metabolic comorbidities (27). In a group of 234 mono-infected 
patients that had Fibroscan for clinical reasons, 20 (8%) were reported with stiffness values >9.3 KPa, although there is an evident 
selection bias (24). Finally, literature reporting data on liver biopsy is limited. In a cohort of 62 patients with increased transaminases in 
HIV mono-infection, 73% of patients had NAFLD, 55% had NASH and 31% had evidence of fibrosis (26). In a prospective study of 198 HIV 
mono-infected subjects, the prevalence of liver fibrosis assessed by Fibroscan was 10.6% (21 patients) and NAFLD detected at histology 
accounted for 50% of all etiologies (30). Our data are consistent with the above results and further provide the missing link of high 
stiffness values in such patients with NAFLD and the metabolic syndrome.  
On the other hand, there was a discordance of TE with APRI and FIB4 in the diagnosis of significant and advanced fibrosis respectively, 
as the majority of them had normal FIB4 and APRI values (95.2% and 93.6%, respectively), while the prevalence of significant and 
advanced fibrosis as assessed by APRI and FIB-4 was 1.2% and 0.8% respectively. The FIB4 results are in line with previous data, as in a 
cohort of 1310 HIV infected women values ≥3.25 were found in only 1.3% of the mono-infected cohort of patients, rising up to 8.6% in 
the co-infected one (31). Similarly, in a cohort of 83 HIV mono-infected patients, only one of them was diagnosed with advanced fibrosis 
(19). In another retrospective observational study FIB4 values >3.25 were found in 31 (4%) of 796 HIV mono-infected patients, but an 
undisclosed element of alcohol consumption might have contributed this slightly higher rate (32). Conversely, a higher prevalence at 8% 
of APRI values >1.5 was found in 432 HIV mono-infected patients (33). However, in this study fibrosis was associated with diabetes and 
the cohort was made of more than 50% of overweight subjects, thus these metabolic features could possibly have contributed to the 
higher prevalence of fibrosis. Moreover, in an observational prospective study on 1112 HIV mono-infected subjects, FIB4 values >3.25 
and APRI values >1.45 were found in the 3.4% and 2.9% of the cohort respectively, with a moderate concordance between the scores. 
Interestingly, the progression of liver fibrosis, as assessed by the transition to higher values of both scores, was prevented by an early 
antiviral therapy initiation (28).  
We believe that this discordance is attributed mostly to false negative results of the simple NITs rather than TE. While the majority of 
our cohort had normal transaminases, FIB4 and APRI have been developed and validated in patients with abnormal liver enzymes. 
Therefore, their diagnostic accuracy in patients with normal transaminases is unknown and possibly suboptimal. Moreover, APRI is 
suboptimal in patients with NAFLD and has only been sufficiently validated in patients with HCV or HBV. Finally, TE is superior to simple 
non-invasive serum markers for the diagnosis of significant liver fibrosis (22, 34).  
This study has some limitations. Firstly, it is a cross sectional study, so it is not possible to define the consecutive steps leading to the 
development of both steatosis and fibrosis in HIV infected patients. Moreover, a long-term follow-up longitudinal study would be needed 
to truly assess the significance of steatosis and fibrosis in this cohort and the potential effects of modifications in the anti-retroviral 
therapy regime. TE would be of value in such a scenario as it would provide serial non-invasive measurements, with each patient serving 
as his own control. Secondly, the detection of steatosis by ultrasound could have led to an underestimation of the actual prevalence of 
NAFLD, as the specificity of this technique is suboptimal. Although histology was not available, it would be unethical to biopsy otherwise 
healthy patients.  Furthermore, non-invasive fibrosis tests are increasingly used and are now part of diagnostic algorithms and routine 
clinical practice (35, 36). Thirdly, the small number of patients considered does not allow our results to be conclusive, as they need to 
be further confirmed in larger cohorts. Finally, the treatment used in this cohort does not reflect current practice and could be in part 
responsible for the relatively high prevalence of steatosis in this cohort. Although we cannot exclude that high stiffness values in some 
patients, particularly those on didanosine, were due to nodular regenerative hyperplasia, the prevalence of this condition is very low 
and therefore would not influence the main conclusions (37).  
In conclusion, liver fibrosis is likely to develop in asymptomatic HIV infected patients independently of HCV or HBV co-infection. This is 
more likely associated to NAFLD and usually manifests with normal transaminases even in patients with abnormal stiffness values. 
Possibly HAART or HIV infection itself might play a key role, even if a significant correlation was not supported by our data. Therefore, 
non-invasive screening for the presence of NAFLD and fibrosis should be offered in HIV mono-infected patients as part of their routine 
clinical care. This would allow the timely diagnosis of chronic liver disease and would allow for the instigation of preventative measures 
(38). Given the association of NAFLD with cardiovascular morbidity and mortality, aggressive treatment of the MS components should 
be offered in patients with HIV and steatosis (39). 
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Table 1. Characteristics of the cohort of HIV mono-infected patients 
Characteristics N= 125  
Gender, male (%) 114 (91) 
Age, years 39.5 ± 10.3 
Current smoker, n(%) 49 (45.4) 
BMI, Kg/m2 24.6 ± 2.9  
WC, cm 91.8 ± 14.3 
AST, IU/L 23 (11-188) 
ALT, IU/L 26 (9-315) 
GGT, U/L 27 (10-200) 
ALP, U/L 76 ± 21 
Hb, g/dL 15.1 ± 2.4 
PTL, /cm3 250 ± 61  
WC (n°/10^3) 6956 ± 2365 
HOMA index 1.45 (0.26-7.07) 
IR, n (%) 6 (7.1) 
Total Cholesterol, mmol/L 210 ± 50 
LDLc, mmol/L 136 ± 45 
HDL, mmol/L 42 ± 14 
Tryglicerides, mmol/L 137 (25-1340) 
MS, n(%) 12 (9.8) 
Diabetes, n(%) 5 (6.3) 
Hypertension, n(%) 12 (9.7) 
Lipodystrophy, n(%) 35 (36.8) 
Age at infection years 29.1 ± 8.5 
Duration of infection , years 6 (0-26) 
No previous HIV treatment, n (%) 35 (28%) 
Current treatment, n(%) 85 (68) 
thymidine analogues, n(%) 36 (29.5) 
PIs, n(%) 55 (45.1) 
NNRTIs, n(%) 33 (27) 
Duration of treatment, years 3 (0-17) 
HIV-RNA, copies/mL 333732 ± 144520 
Lymphocytes CD4+, /mm3 480 (9-1740)  
US steatosis, n(%) 61 (55) 
Grade I, n(%) 40 (36) 
Grade II, n(%) 17 (15.3) 
Grade III, n(%) 4 (3.6) 
Stiffness, KPa 5.8 ± 1.9 
Stiffness >7.4 KPa, n(%) 22 (17.6) 
Stiffness > 10 KPa, n(%) 5 (4) 
FIB4 score  
≤1.45, n(%) 119 (95.2) 
1.46-3.24, n(%) 5 (4) 
≥3.25, n(%) 1 (0.8) 
APRI index  
≤0.5, n(%) 117 (93.6) 
0.51-1.49, n(%) 6 (4.8) 
≥1.5, n(%) 2 (1.6) 
§data expressed as mean ± SD for quantitative variables with normal distribution; data expressed as median (IQR) for quantitative variables without normal distribution. 
Abbreviations: BMI, body mass index; WC, waist circumference; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ-glutamyl 
transpeptidase; ALP, alkaline phosphatase; Hb, haemoglobin; PLT, platelets; IR, insulin resistance; MS, metabolic syndrome; PIs, protease inhibitors; 
NNRTIs, non-nucleoside reverse transcriptases. 
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Table 2. Variables associated with the presence of liver steatosis in the cohort of HIV mono-infected patients 
 
Patient characteristics 
No steatosis 
(N= 50) 
Steatosis  
(N=61) 
Univariate analysis  
P value 
Multivariate analysis 
P value           OR (95% CI) 
Age, years 36.7 ± 10.5 42.6 ± 9.5 0.002 0.03 1.082 (1.01-1.16) 
Sex, males (%) 42 (84) 59 (96.7) 0.041 0.02 14.64 (1.44-148.17) 
Smoking, n(%) 15 (30) 28 (45.9) 0.247   
Alcohol abuse, n (%) 1 (2) 4 (6.5) 0.378   
BMI, Kg/m2 23.4 ± 2.2 25.6 ± 3 0.001 -  
Waist circumference, cm 84.8 ± 17.9 97.7 ± 8.7 <0.001 -  
HOMA index 1.26 ± 0.65 2.01 ± 1.37 0.002 0.03 2.56 (1.101-5.96) 
Insulin resistance, n (%) 1 (2) 5 (8.2) 0.216   
Diabetes mellitus, n (%) 1 (2) 6 (9.8) 0.124   
PLT, x103/mm3 253 ± 54 248 ± 65 0.589   
Serum LDL cholesterol, mg/dL 134 ± 45 139 ± 48 0.532   
Serum HDL cholesterol <40 mg/dl 
(male) and < 50 mg/dl (female), n(%) 
26 (52) 35 (57.3) 0.702   
Serum triglycerides > 150 mg/dl, 
n(%) 
12 (24) 35 (57.4) <0.001 -  
Hypertension, n(%) 3 (6) 7 (11.5) 0.342   
Metabolic syndrome, n(%) 1 (2) 11 (18) 0.006 NS  
Lipodystrophy, n(%) 12 (24) 21 (34.4) 0.125   
ALT, IU/L 28 ± 13 35 ± 38 0.1   
AST, IU/L 29 ± 24 27 ± 21 0.487   
ALP, U/L 74 ± 24 76 ± 20 0.738   
GGT, U/L 28 ± 18 43 ± 35 0.001 0.04 1.037 (1.007-1.075) 
Duration of infection, years 7 ± 6.5 8.2 ± 6.8 0.418   
No previous HIV treatment, n (%) 18 (36) 13 (22) 0.066 NS  
Current treatment, n (%) 30 (60) 45 (73.8) 0.155   
Protease inhibitors 19 (38) 28 (45.9) 0.437   
Thymidine analogues 15 (30) 16 (26.2) 0.831   
NNRTIs 13 (26) 18 (29.5) 0.675   
Duration of treatment, years 4.3 ± 4.6 5.3 ± 4.8 0.191   
CD4+ <200/mm3 4 (8) 4 (6.5) 1   
HIV-RNA > 100000 copies/mL 3 (6) 5 (8.2) 0.728   
 
Abbreviations: BMI, body mass index; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ-glutamyl transpeptidase; ALP, 
alkaline phosphatase; Hb, haemoglobin; PLT, platelets; NNRTIs, non-nucleoside reverse transcriptases. 
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Table 3. Variables associated with the presence of liver fibrosis in the cohort of HIV mono-infected patients  
 
Patient characteristic 
Stiffness < 7.4 KPa 
(N= 103) 
Stiffness > 7.41 KPa  
(N=22) 
Univariate analysis  
P value 
Multivariate analysis 
P value           OR (95% CI) 
Age, years 38.4 ± 9.8 44.8 ± 11.2 0.008 NS  
Sex, males (%) 92(89.3) 22(100) 0.108   
Smoking, n(%) 42 (40.8) 7 (11.7) 0.8   
Alcohol abuse, n (%) 3 (2.9) 2 (9) 0.232   
BMI, Kg/m2 24.2 ± 2.5  26 ± 3.9 0.011 -  
Waist circumference, cm 90.5 ± 14.2 100.6 ± 11.4 0.036 -  
HOMA index 1.71 ± 1.18  1.3 ± 0.62 0.33   
Insulin resistance, n(%) 6 (5.8) 0 (0) 0.419   
Diabetes mellitus, n(%) 4 (3.9) 3 (13.6) 0.094   
PLT, x103/mm3 254 ± 61 224 ± 56 0.033 NS  
Serum LDL cholesterol, mg/dL 136 ± 44 136 ± 50 0.994   
Serum HDL cholesterol <40 mg/dl 
(male) and < 50 mg/dl (female), n(%) 
52 (50.4) 13 (59) 0.491   
Serum triglycerides > 150 mg/dl, 
n(%) 
39 (37.9) 10 (4.5) 0.631   
Hypertension, n(%) 6 (5.8) 6 (27.3) 0.006 -  
Metabolic syndrome, n(%) 6 (5.8) 6 (27.3) 0.004 0.05 3.99 (0.992-16.09) 
Lipodystrophy, n(%) 31 (30) 4 (18.1) 0.279   
ALT, IU/L 28 ± 13 43 ± 62  0.159   
AST, IU/L 26 ± 18  31 ± 32 0.699   
ALP, U/L 76 ± 23 75 ± 14 0.901   
GGT, U/L 34 ± 27  44 ± 34 0.137   
Duration of infection, years 7.5 ± 6.5 6.3 ± 6.5 0.66   
No previous HIV treatment , n (%) 28 (27) 7 (32) 0.42   
Current treatment, n(%) 70 (68) 15 (68.2) 0.599   
Protease inhibitors 43 (41.7) 12 (54.5) 0.352   
Thymidine analogues 30 (29.1) 6 (27.3) 1   
NNRTIs 30 (29.1) 3 (13.6) 0.184   
Duration of treatment, years 4.5 ± 4.3 6.4 ± 6.1 0.252   
CD4+ <200/mm3 7 (6.8) 3 (13.6) 0.379   
HIV-RNA > 100000 copies/mL 7 (6.8) 2 (9) 0.658   
US steatosis, n(%) 48 (46.6) 13 (59) 0.457   
Grade of steatosis    0.026 NS  
Grade I, n(%) 
Grade II, n(%) 
Grade III, n(%) 
35 
11 
2 
5 
6 
2 
 
 
Abbreviations: BMI, body mass index; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ-glutamyl transpeptidase; ALP, 
alkaline phosphatase; Hb, haemoglobin; PLT, platelets; NNRTIs, non-nucleoside reverse transcriptases. 
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Table 4. Liver stiffness values stratified for APRI index and FIB4 score in the whole cohort 
of HIV mono-infected patients (n=125) 
 Liver stiffness values (KPa) 
 ≤7.4 (n=103) >7.4 (n=22) ≤10 (n=120) >10 (n=5) 
APRI<0.5    
(n=117) 
97 20 113 4 
APRI>1.5    
(n=2) 
1 1 2 0 
FIB4<1.45  
(n=119) 
100 19 115 4 
FIB4>3.25  
(n=1) 
1 0 1 0 
 
 
 
